Hartman Institute for Therapeutic Organ Regeneration

Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes.

TitleCytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes.
Publication TypeJournal Article
Year of Publication2006
AuthorsJin DK, Shido K, Kopp H-G, Petit I, Shmelkov SV, Young LM, Hooper AT, Amano H, Avecilla ST, Heissig B, Hattori K, Zhang F, Hicklin DJ, Wu Y, Zhu Z, Dunn A, Salari H, Werb Z, Hackett NR, Crystal RG, Lyden D, Rafii S
JournalNat Med
Volume12
Issue5
Pagination557-67
Date Published2006 May
ISSN1078-8956
KeywordsAnimals, Blood Platelets, Chemokine CXCL12, Chemokines, CXC, Cytokines, Humans, Ischemia, Matrix Metalloproteinase 9, Mice, Mice, Inbred C57BL, Mice, Knockout, Neovascularization, Physiologic, Receptors, CXCR4, Regeneration, Stem Cell Factor, Stem Cells, Thrombocytopenia, Thrombopoietin, Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor Receptor-1
Abstract

The mechanisms through which hematopoietic cytokines accelerate revascularization are unknown. Here, we show that the magnitude of cytokine-mediated release of SDF-1 from platelets and the recruitment of nonendothelial CXCR4+ VEGFR1+ hematopoietic progenitors, 'hemangiocytes,' constitute the major determinant of revascularization. Soluble Kit-ligand (sKitL), thrombopoietin (TPO, encoded by Thpo) and, to a lesser extent, erythropoietin (EPO) and granulocyte-macrophage colony-stimulating factor (GM-CSF) induced the release of SDF-1 from platelets, enhancing neovascularization through mobilization of CXCR4+ VEGFR1+ hemangiocytes. Although revascularization of ischemic hindlimbs was partially diminished in mice deficient in both GM-CSF and G-CSF (Csf2-/- Csf3-/-), profound impairment in neovascularization was detected in sKitL-deficient Mmp9-/- as well as thrombocytopenic Thpo-/- and TPO receptor-deficient (Mpl-/-) mice. SDF-1-mediated mobilization and incorporation of hemangiocytes into ischemic limbs were impaired in Thpo-/-, Mpl-/- and Mmp9-/- mice. Transplantation of CXCR4+ VEGFR1+ hemangiocytes into Mmp9-/- mice restored revascularization, whereas inhibition of CXCR4 abrogated cytokine- and VEGF-A-mediated mobilization of CXCR4+ VEGFR1+ cells and suppressed angiogenesis. In conclusion, hematopoietic cytokines, through graded deployment of SDF-1 from platelets, support mobilization and recruitment of CXCR4+ VEGFR1+ hemangiocytes, whereas VEGFR1 is essential for their angiogenic competency for augmenting revascularization. Delivery of SDF-1 may be effective in restoring angiogenesis in individuals with vasculopathies.

DOI10.1038/nm1400
Alternate JournalNat Med
PubMed ID16648859
PubMed Central IDPMC2754288
Grant ListR01 HL061849-04 / HL / NHLBI NIH HHS / United States
R01 HL058707-04 / HL / NHLBI NIH HHS / United States
HL67839 / HL / NHLBI NIH HHS / United States
P01 HL067839 / HL / NHLBI NIH HHS / United States
R01 AG023218-03 / AG / NIA NIH HHS / United States
R01 HL058707-03 / HL / NHLBI NIH HHS / United States
R01 HL061849-03S1 / HL / NHLBI NIH HHS / United States
R01 HL061849-05 / HL / NHLBI NIH HHS / United States
HL59312 / HL / NHLBI NIH HHS / United States
P01 HL067839-010004 / HL / NHLBI NIH HHS / United States
P01 HL067839-02 / HL / NHLBI NIH HHS / United States
R01 HL061849-02 / HL / NHLBI NIH HHS / United States
/ HHMI / Howard Hughes Medical Institute / United States
R01 AG023218 / AG / NIA NIH HHS / United States
U01 CA105379 / CA / NCI NIH HHS / United States
R01 HL075234-04 / HL / NHLBI NIH HHS / United States
P01 HL067839-020004 / HL / NHLBI NIH HHS / United States
P01 HL059312 / HL / NHLBI NIH HHS / United States
R01 HL061849-03 / HL / NHLBI NIH HHS / United States
R01 HL061849 / HL / NHLBI NIH HHS / United States
P01 HL067839-050004 / HL / NHLBI NIH HHS / United States
P01 HL067839-030004 / HL / NHLBI NIH HHS / United States
HL66592 / HL / NHLBI NIH HHS / United States
P01 HL059312-10 / HL / NHLBI NIH HHS / United States
R01 HL075234 / HL / NHLBI NIH HHS / United States
U01 CA105379-04 / CA / NCI NIH HHS / United States
P01 HL067839-040004 / HL / NHLBI NIH HHS / United States
R01-HL075234 / HL / NHLBI NIH HHS / United States

Weill Cornell Medicine
Hartman Institute for Therapeutic Organ Regeneration
1300 York Ave, Box 136 New York, NY 10065